| Full Name | Dr Jian Hu |
|---|---|
| Gender | Male |
| Speciality | Pain Management |
| Experience | 40 Years |
| Location | 855 King Ave, Athens, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295939452 | NPI | - | NPPES |
| 12274814 | Other | CAQH NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2081P2900X | Physical Medicine & Rehabilitation - Pain Medicine | 60273 (Georgia) | Secondary |
| 208100000X | Physical Medicine & Rehabilitation | 60273 (Georgia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Athens Orthopedic Clinic, Pa | 5991600181 | 69 |
News Archive
Synapse Biomedical Inc. announces today that they have received the U.S. Food and Drug Administration (FDA) designation of the NeuRx Diaphragm Pacing System (DPS) as a Humanitarian Use Device (HUD) for amyotrophic lateral sclerosis (ALS) patients with a stimulatable diaphragm who are experiencing chronic hypoventilation and has now submitted for Humanitarian Device Exemption (HDE) approval.
Cancer becomes life threatening when tumor cells start leaving their primary site. They travel through the lymph and blood streams to other tissues where they grow into metastases. This transition to malignancy is associated with characteristic changes in the cancer cells. The activity of several genes is reprogrammed and, thus, the production of proteins anchoring cells to a tissue is reduced. On the other hand, the amount of surface markers which make a cancer cell mobile increases.
Curemark, LLC,, a drug research and development company focused on the treatment of neurological diseases, announced that the company has opened clinical trial enrollment for CM-AT, its autism treatment, at the University of Pittsburgh and the Alexian Brothers Behavioral Health Hospital in Hoffman Estates, Illinois, near Chicago. A total of 12 sites nationwide are recruiting patients for CM-AT Phase III clinical trials.
The research group led by Dr. Koji Hasegawa, Director of the Translational Research Division at the National Hospital Organization Kyoto Medical Center and Dr. Tatsuya Morimoto, Professor at the Molecular Medicine School of Pharmaceutical Sciences, University of Shizuoka, announced today based on the recent human clinical trials, that Theracurmin has continuously shown positive impact on human diastolic functions.
› Verified 5 days ago
| Entity Name | Athens Orthopedic Clinic, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063495299 PECOS PAC ID: 5991600181 Enrollment ID: O20031201000709 |
News Archive
Synapse Biomedical Inc. announces today that they have received the U.S. Food and Drug Administration (FDA) designation of the NeuRx Diaphragm Pacing System (DPS) as a Humanitarian Use Device (HUD) for amyotrophic lateral sclerosis (ALS) patients with a stimulatable diaphragm who are experiencing chronic hypoventilation and has now submitted for Humanitarian Device Exemption (HDE) approval.
Cancer becomes life threatening when tumor cells start leaving their primary site. They travel through the lymph and blood streams to other tissues where they grow into metastases. This transition to malignancy is associated with characteristic changes in the cancer cells. The activity of several genes is reprogrammed and, thus, the production of proteins anchoring cells to a tissue is reduced. On the other hand, the amount of surface markers which make a cancer cell mobile increases.
Curemark, LLC,, a drug research and development company focused on the treatment of neurological diseases, announced that the company has opened clinical trial enrollment for CM-AT, its autism treatment, at the University of Pittsburgh and the Alexian Brothers Behavioral Health Hospital in Hoffman Estates, Illinois, near Chicago. A total of 12 sites nationwide are recruiting patients for CM-AT Phase III clinical trials.
The research group led by Dr. Koji Hasegawa, Director of the Translational Research Division at the National Hospital Organization Kyoto Medical Center and Dr. Tatsuya Morimoto, Professor at the Molecular Medicine School of Pharmaceutical Sciences, University of Shizuoka, announced today based on the recent human clinical trials, that Theracurmin has continuously shown positive impact on human diastolic functions.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jian Hu, MD 1765 Old West Broad St Bldg 2-200, Athens, GA 30606-2887 Ph: (706) 549-1663 | Dr Jian Hu, MD 855 King Ave, Athens, GA 30606-2837 Ph: (706) 549-1663 |
News Archive
Synapse Biomedical Inc. announces today that they have received the U.S. Food and Drug Administration (FDA) designation of the NeuRx Diaphragm Pacing System (DPS) as a Humanitarian Use Device (HUD) for amyotrophic lateral sclerosis (ALS) patients with a stimulatable diaphragm who are experiencing chronic hypoventilation and has now submitted for Humanitarian Device Exemption (HDE) approval.
Cancer becomes life threatening when tumor cells start leaving their primary site. They travel through the lymph and blood streams to other tissues where they grow into metastases. This transition to malignancy is associated with characteristic changes in the cancer cells. The activity of several genes is reprogrammed and, thus, the production of proteins anchoring cells to a tissue is reduced. On the other hand, the amount of surface markers which make a cancer cell mobile increases.
Curemark, LLC,, a drug research and development company focused on the treatment of neurological diseases, announced that the company has opened clinical trial enrollment for CM-AT, its autism treatment, at the University of Pittsburgh and the Alexian Brothers Behavioral Health Hospital in Hoffman Estates, Illinois, near Chicago. A total of 12 sites nationwide are recruiting patients for CM-AT Phase III clinical trials.
The research group led by Dr. Koji Hasegawa, Director of the Translational Research Division at the National Hospital Organization Kyoto Medical Center and Dr. Tatsuya Morimoto, Professor at the Molecular Medicine School of Pharmaceutical Sciences, University of Shizuoka, announced today based on the recent human clinical trials, that Theracurmin has continuously shown positive impact on human diastolic functions.
› Verified 5 days ago
Nidhi Patel, PT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 2319 Prince Ave, Athens, GA 30606 Phone: 706-425-8888 | |
Cora Hrebec, PTA Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 665 Gaines School Rd, Athens, GA 30605 Phone: 706-369-8115 Fax: 706-369-8116 | |
Dr. Joseph Mark Savitz, DO Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 855 King Ave, Athens, GA 30606 Phone: 706-549-1663 Fax: 706-546-8792 | |
Jesse Ferguson, DPT Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 665 Gaines School Rd, Athens, GA 30605 Phone: 706-369-8115 Fax: 706-369-8116 | |
Kelly A Dixon-martin, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 4017 Atlanta Hwy Ste B, Athens, GA 30606 Phone: 706-389-2222 Fax: 706-389-2221 | |
Bogdan Cristian Jaliu, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 2142 W Broad St, Bldg 100 Ste 200, Athens, GA 30606 Phone: 706-548-6881 Fax: 706-546-0821 |